Content
and Copyright
i
Superseded
This Document Has Been Replaced By:
i
Retired
This Document Has Been Retired
i
Up-to-date Information
This is the latest update:
Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020
-
Published Date:
01/08/2021
-
Publisher's site:
-
Status:current
-
Source:Recommendations and Reports / January 8, 2021 / 70(1);1ā12
-
Series:
-
Language:English
-
[PDF-330.66 KB]
Details:
-
Personal Author:
-
Corporate Authors:
-
Description:This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the rVSVĪG-ZEBOV-GP Ebola vaccine (Ervebo) in the United States. The vaccine contains rice-derived recombinant human serum albumin and live attenuated recombinant vesicular stomatitis virus (VSV) in which the gene encoding the glycoprotein of VSV was replaced with the gene encoding the glycoprotein of Ebola virus species Zaire ebolavirus. Persons with a history of severe allergic reaction (e.g., anaphylaxis) to rice protein should not receive Ervebo. This is the first and only vaccine currently licensed by the Food and Drug Administration for the prevention of Ebola virus disease (EVD). These guidelines will be updated based on availability of new data or as new vaccines are licensed to protect against EVD.
-
Subject:
-
Document Type:
-
Place as Subject:
-
Collection(s):
-
Main Document Checksum:
- File Type:
-
Supporting Files:
text/html
No Related Documents.
Email
CDC-INFO
